3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Advanced Solid Tumors
1
Interventions
Sorafenib
37
Nivolumab
21
pembrolizumab
18
Bevacizumab
12
Cyclophosphamide
10
durvalumab
9
fludarabine
8
atezolizumab
8
Magnetic Resonance Spectroscopy
8
lenvatinib
7
Radiosurgery
7
Ipilimumab
7
Radiotherapy
6
Irinotecan
6
Oxaliplatin
5
Leucovorin
5
tremelimumab
4
toripalimab
4
tislelizumab
4
sintilimab
4
cabozantinib
4
budigalimab
4
Specimen Handling
4
Sirolimus
4
Interleukin-2
4
Fluorouracil
4
Doxorubicin
4
Capecitabine
4
130-nm albumin-bound paclitaxel
4
spartalizumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Carcinoma, Hepatocellular
×
ascrinvacumab
×
Clear all
NCT01337050
2015-10-28
Asian Phase I Study Of PF-03446962
Pfizer
Phase 1
Completed
36 enrolled
24 charts